Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.57 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.57 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.57 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1362228 | 0.87 | RAB9A (0.65) | BCHETRPC3TRPC4TRPC5RAB9A | |
| Hydrochloric Acid SCHEMBL1360590 | 0.85 | RAB9A (0.63) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL6963533 | 0.81 | ALDH1A1 (0.51) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2674051 | 0.79 | RAB9A (0.71) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL31147200 | 0.79 | RAB9A (0.71) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL19374547 | 0.79 | BCHE (0.67) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL31329349 | 0.77 | MEN1 (0.66) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL28801773 | 0.77 | MEN1 (0.66) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL8464091 | 0.75 | BCHE (0.82) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL5844930 | 0.75 | BCHE (0.67) | BCHETRPC3TRPC4TRPC5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167359-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-10 | — | — | US | claimed |
| US-20050054705-A1 | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | claimed |
| US-8067614-B2 | N-substituted (benzoimidazol-2-yl)phenylamines, processes for their preparation, their use as a medicament or diagnostic aid, and a medicament comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20100168196-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-01 | — | — | US | disclosed |
| US-20080167359-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20050054705-A1 | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167359-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SLC10A1, SLC9A3, ABCB11 | BCHE 1201/4885TRPC3 637/4885TRPC4 1190/4885 |
| US-20100168196-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SLC10A1, SLC9A3, ABCB11 | BCHE 1201/4885TRPC3 637/4885TRPC4 1190/4885 |
| US-20050054705-A1 | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | SLC10A1, SLC9A3, NHERF1 | BCHE 1056/4885TRPC3 722/4885TRPC4 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.